Repligen Corp vs Johnson & Johnson
RGEN vs JNJ — side-by-side comparison from reported financials. RGEN leads 1, JNJ leads 9 of 10 comparable metrics.
Repligen Corp
RGEN · Healthcare
$173.88+6.13%Mixed
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | RGEN | JNJ |
|---|---|---|
| Price | $173.88 | $261.79 |
| Market cap | $11.0B | $631B |
| Revenue (TTM) | $785M | $97.9B |
| Revenue growth | -2.7% | +5.6% |
| Net margin | 5.3% | 21.5% |
| Free cash flow | $112M | $22.2B |
| Net cash (debt) | $225M | ($27.8B) |
| 1-year price return | +16.8% | +37.0% |
| P/E | 265.8 | 29.9 |
| P/E vs own history (cheap-side %) | 2% | 16% |
| Dividend yield | — | 2.00% |
| Return on equity | 2% | 26% |
| CV checks passed | 7 of 10 | 10 of 10 |
| Employees | 2,000 | 140,800 |
Full résumé-style profiles: RGEN CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.